


The Diagnostic Audit; Scanning for Errors before the FDA Does

Victoria LaBush BS, CCRP, Hannah Cressman RHIA, CCRP, Clarice Zuccaro BA, CCRP, Rachael Gorney MA, CCRP, Kelly Schneider BS, CCRP

Background

The Phase I MDT Clinical Research Coordinator (CRC) team launched an internal quality-improvement initiative to strengthen audit readiness, enhance coordinator performance, and reduce documentation inconsistencies.

- We designed and implemented a standardized internal audit template and tracking spreadsheet for patient research shadow charts.
- This structured framework ensures consistent evaluation of key chart components, supports adherence to protocol requirements and departmental Standard Operating Procedures (SOPs), and provides coordinators with clear, actionable feedback.
- By establishing a uniform review process, the initiative promotes accuracy, improves documentation quality, and reinforces a culture of continuous compliance across the Phase I MDT.



- A tracking spreadsheet was created to manage the internal audit lifecycle
- All enrolled patients are added to the tracker and weekly email notifications are distributed to the team with audit due dates

Outcomes

Focused retraining was implemented by assessing CRC adherence to protocols, departmental processes and policies. This strategic evaluation allowed for the identification of specific performance gaps, ensuring operational consistency and reinforcing the highest standards of clinical trial execution.

Lessons Learned & Future Directions

- The internal audit process provides continued support for Phase I CRCs. Standardized constructive feedback ensures the CRC competency, protocol comprehension, and adherence to institutional SOPs.
- This process was well received by the CRCs, equipping them with functional tools to execute tasks thoroughly and confidently.
- This process was also adapted by the Lung MDT CRCs.
- Continued use of this process will further the understanding of standardized methodologies and promote improvement within the ever-evolving scope of clinical trials.

Audit Template Example

Informed Consent Process				
Description	Comments	Finding(s)	OK	NA
A. Consent obtained prior to study procedures			<input type="checkbox"/>	<input type="checkbox"/>
B. Correct version of consent was used			<input type="checkbox"/>	<input type="checkbox"/>
C. Consent has required signatures, initials, and dates			<input type="checkbox"/>	<input type="checkbox"/>
D. Documentation of optional consent(s) presented to patient			<input type="checkbox"/>	<input type="checkbox"/>
E. Optional consent(s) signed, dated and filed			<input type="checkbox"/>	<input type="checkbox"/>
F. Consenting NTF			<input type="checkbox"/>	<input type="checkbox"/>
G. Oncore consenting notice			<input type="checkbox"/>	<input type="checkbox"/>
H. IRT/OPEN consent notice			<input type="checkbox"/>	<input type="checkbox"/>
I. Were errors addressed per GCP			<input type="checkbox"/>	<input type="checkbox"/>
J. Was re-consenting required and documented			<input type="checkbox"/>	<input type="checkbox"/>
K. Treatment past progression consent			<input type="checkbox"/>	<input type="checkbox"/>
L. Short form consent used			<input type="checkbox"/>	<input type="checkbox"/>
M. Full consent translated			<input type="checkbox"/>	<input type="checkbox"/>
N. Additional consent comments				

Goals

Goal #1

- Maintain continuous audit readiness

Goal #2

- Provide oversight and support to Phase I CRCs

Goal #3

- Identify performance trends and areas for improvement

Methods Implemented

- Cycle 1 audits are mandatory for all CRCs to verify protocol execution, source documentation accuracy, and safety reporting practices.
- For newly onboarded CRCs, the audit period is extended through the first tumor assessment for their first five patients enrolled for additional oversight.
- The internal audit template is categorized into several key domains (noted above)

Conclusion

The internal audit process has successfully evolved from a compliance requirement into a vital support tool for our CRCs. By prioritizing standardized, constructive feedback, we have enabled our team to navigate the complexities of Phase I trials with increased confidence and precision. We have fostered a culture of continuous improvement and operational excellence within our team.